Moderna's chief legal officer Shannon Klinger to retire under agreement filed November 13
Klinger will remain through March 2027 under a retirement deal that includes payments tied to the outcome of ongoing litigation.
SEC filing
47 stories
Klinger will remain through March 2027 under a retirement deal that includes payments tied to the outcome of ongoing litigation.
SEC filing
A record notice: the source is linked, and no summary was written because none passed the fact check.
Drugs@FDA, FDA (2)
Eikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.
SEC filing (12)
The voucher is intended to support a future filing in BioNTech's late-stage oncology pipeline, pending customary closing conditions.
SEC filing
Arbutus reported a $337.5 million cash position for the third quarter of 2026 and said the FDA cleared AB-101 for further U.S. development while it widened LNP patent litigation against Pfizer and BioNTech.
SEC filing
An FDA record shows the agency had previously granted accelerated approval to encorafenib paired with cetuximab and mFOLFOX6 before later converting to traditional approval for BRAF V600E-mutant metastatic colorectal.
FDA (4)
The agency granted traditional approval on April 29, 2024, moving tisotumab vedotin-tftv beyond its earlier accelerated clearance.
FDA (2)
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)
The company, formerly Adial Pharmaceuticals, reconstituted its board and committees effective November 3, 2026, while also disclosing conversion of preferred stock tied to its Azora acquisition.
SEC filing
The agency cleared inotuzumab ozogamicin for children 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia on March 6, 2024.
FDA
The specialty vaccine company said it will hold a live webcast to discuss results and give a business update.
SEC filing
The board unanimously elected Guegan, who had served as interim finance chief since August, to the role with a $1.3 million base salary.
SEC filing
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The open-label extension trial, which had enrolled 42 participants, was stopped as of a business decision unrelated to safety or efficacy, according to the registry record updated November 2, 2026.
ClinicalTrials.gov
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The endocrine and rare disease drugmaker named the former Viatris and Pfizer executive to a newly created board seat and its audit committee, effective November 2, 2026.
SEC filing
The commercial-stage dermatology company added the former AbbVie chief medical officer effective October 23, 2026, expanding its board to eleven members.
SEC filing
Enrollment closed after 11 patients for strategic business reasons, not safety, with Phase 2 and drug interaction portions never started.
ClinicalTrials.gov
The company expanded its board to seven members and named Schayowitz a Class III director effective October 23, 2026.
SEC filing
The agency cleared a priority-review supplemental application for the PARP inhibitor talazoparib tosylate, according to FDA records.
Drugs@FDA
The approval covers metastatic prostate cancer patients with HRR gene mutations who have not yet received or are still responding to androgen pathway modulation.
FDA, Drugs@FDA (2)
Arbutus Biopharma said it can resume U.S. clinical development of AB-101, its oral PD-L1 inhibitor for chronic hepatitis B, after the FDA removed the hold.
SEC filing, Drugs@FDA (2)
Eloxx Pharmaceuticals expanded its board and named a new chief medical officer while detailing its global Phase 2 EXPRESS trial for exaluren in nonsense-mutation ADPKD.
SEC filing
Farrow, who serves as CFO and chief strategy officer of Tarsus Pharmaceuticals, joins Lisata's Audit Committee as the board expands to eight members.
SEC filing
The agency cleared tucatinib with trastuzumab and pertuzumab as a maintenance therapy following induction treatment, the FDA said.
Drugs@FDA, FDA (2)
The company stopped NCT03307980 for sponsor reasons, not safety or efficacy, and will move participants to a long-term follow-up study.
ClinicalTrials.gov
The appointment, effective October 1, 2026, follows Celcuity's first FDA approval and the September 30 US launch of REVTORPYK for advanced breast cancer.
SEC filing (2)
The board's appointment, effective September 29, 2026, comes with a $560,000 base salary, a $35,000 signing bonus, and inducement equity grants.
SEC filing
Zhang, formerly Novartis International's Chief Commercial Officer, succeeds interim CEO Alan Bash, who returns to lead the CARVYKTI business.
SEC filing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing
Medicus Pharma Inc. licensed rights to Pfizer's early clinical-stage asset CD228V, agreeing to pay up to $27 million in near-term fees plus potential milestones exceeding $1 billion.
SEC filing